The stringent exclusion criteria used to eliminate potential confounders of sarcopenia, along with the widespread use of GLP-1 analogs and/or SGLT2 inhibitors in routine care at our tertiary center, may have contributed to the limited number of eligible patients. The gene discussed is SLC5A2; the disease is sarcopenia.